Medications for Systemic Fungal Infections
Medication | Uses | Potential Adverse Effects |
|---|---|---|
Most fungal infections | Conventional formulation: Acute infusion reactions, neuropathy, gastrointestinal (GI) upset, renal failure, anemia, thrombophlebitis, hearing loss, rash, hypokalemia, hypomagnesemia | |
Lipid formulations: Infusion reactions*, renal failure* | ||
Candidiasis, including candidemia | Hepatitis, diarrhea, hypokalemia, infusion reactions | |
Candidiasis, including candidemia | Phlebitis, headache, GI upset, rash | |
Mucosal and systemic candidiasis Coccidioidal meningitis | GI upset, rash, hepatitis, QT prolongation | |
Candidiasis (systemic) | Pancytopenia due to bone marrow toxicity, neuropathy, nausea, vomiting, hepatic and renal injury, colitis | |
Nausea, vomiting, hepatitis, QT shortening with no evidence of cardiac risk, infusion-related reactions | ||
Dermatomycosis Histoplasmosis, blastomycosis, coccidioidomycosis, sporotrichosis, aspergillosis | Hepatitis, GI upset, rash, headache, dizziness, hypokalemia, hypertension, edema, QT prolongation, heart failure | |
Candidiasis, including candidemia | Phlebitis, hepatitis, rash, headache, nausea, acute intravascular hemolysis | |
Prophylaxis for invasive fungal infection | Hepatitis, GI upset, rash, QT prolongation | |
Candidemia | Photosensitivity, abnormal liver tests, infusion-related reactions (flushing, sensation of warmth, urticaria, nausea, chest tightness) | |
Fusariosis Scedosporiosis | GI upset, transient visual disturbances, peripheral edema, rash, hepatitis, QT prolongation | |
* This adverse effect is less common with lipid formulations than with the conventional formulation. | ||
Candida and cryptococcal infections. | ||
isavuconazonium is equivalent to 200 mg of isavuconazole. | ||